论文部分内容阅读
目的分析不可手术的Ⅲ期非小细胞肺癌的治疗方法及其对预后的影响。方法57例ⅢB期及ⅢA期不可手术切除的非小细胞肺癌患者,其中36例(ⅢA期9例,ⅢB期27例)行静脉化疗加胸部放疗(A组),21例(ⅢA期5例,ⅢB期16例)行支气管动脉灌注联合静脉化疗加胸部放疗(B组)。结果A、B组的中位无进展生存时间(TTP)分别为12.0和11.75个月(P=0.74);中位生存期(MST)分别为17.96及18.33个月(P=0.461),1,2,3年生存率分别为75.0%、29.1%、11.7%及76.2%、23.8%、4.8%,两组之间比较差异无显著性(均为P>0.05)。结论在静脉化疗联合胸部放疗的基础上合并支气管动脉灌注化疗,并不能显著性改善不可手术的Ⅲ期非小细胞肺癌患者的远期生存。
Objective To analyze the treatment of unresectable stage Ⅲ non-small cell lung cancer and its influence on the prognosis. Methods Fifty-seven patients with unresectable non-small cell lung cancer from stage ⅢB and ⅢA were treated with intravenous chemotherapy plus thoracic radiotherapy (group A, n = 36) (group ⅢA, n = 9, stage ⅢB, n = 27) , ⅢB 16 cases) were treated with bronchial artery infusion combined with intravenous chemotherapy plus chest radiotherapy (group B). Results The median progression-free survival time (TTP) in groups A and B were 12.0 and 11.75 months (P = 0.74), respectively. The median survival time was 17.96 and 18.33 months respectively (P = 0.461) The 2-year and 3-year survival rates were 75.0%, 29.1%, 11.7% and 76.2%, 23.8% and 4.8% respectively. There was no significant difference between the two groups (all P> 0.05). Conclusion The combination of intravenous chemotherapy and chest radiotherapy combined with bronchial artery infusion chemotherapy can not significantly improve the long-term survival of patients with unresectable stage Ⅲ non-small cell lung cancer.